Tekla Capital Management’s Veradigm Inc. Common Stock MDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$5.4M Hold
428,580
0.21% 85
2023
Q1
$5.59M Hold
428,580
0.21% 76
2022
Q4
$7.56M Hold
428,580
0.29% 66
2022
Q3
$6.53M Buy
+428,580
New +$6.93M 0.27% 70
2017
Q3
Sell
-47,300
Closed -$604K 161
2017
Q2
$604K Hold
47,300
0.02% 136
2017
Q1
$600K Sell
47,300
-126,300
-73% -$1.5M 0.02% 133
2016
Q4
$1.77M Hold
173,600
0.08% 112
2016
Q3
$2.29M Hold
173,600
0.09% 115
2016
Q2
$2.21M Hold
173,600
0.09% 126
2016
Q1
$2.29M Hold
173,600
0.1% 114
2015
Q4
$2.67M Sell
173,600
-1,604,600
-90% -$23M 0.1% 111
2015
Q3
$22.1M Hold
1,778,200
0.79% 29
2015
Q2
$24.3M Hold
1,778,200
0.88% 23
2015
Q1
$21.3M Buy
1,778,200
+173,600
+11% +$2.12M 0.84% 29
2014
Q4
$20.5M Buy
+1,604,600
New +$20.4M 0.96% 28

Other funds holding MDRX

Tekla Capital Management's MDRX Position: Q2 2023 in Review

Tekla Capital Management held its Veradigm Inc. Common Stock (MDRX) position steady in Q2 2023 at 428,580 shares worth $5.4M. The position accounts for 0.21% of the portfolio, ranked #85.

Tekla Capital Management first reported a position in MDRX in Q4 2014 and has held it in 15 quarters since. The position peaked at $24.3M in Q2 2015. 229 funds tracked by Wall St. Rank hold MDRX as of Q2 2023.

  • Tekla Capital Management held 428,580 shares of Veradigm Inc. Common Stock worth $5.4M as of Q2 2023.
  • Tekla Capital Management left its Veradigm Inc. Common Stock share count unchanged in Q2 2023.
  • Veradigm Inc. Common Stock made up 0.21% of Tekla Capital Management's portfolio in Q2 2023, its #85 holding.
  • Tekla Capital Management first reported a position in Veradigm Inc. Common Stock in Q4 2014 and has held it in 15 quarters since.
  • Tekla Capital Management's Veradigm Inc. Common Stock position peaked at $24.3M in Q2 2015.
  • 229 funds tracked by Wall St. Rank held Veradigm Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.